News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Obecure Initiates Phase II Study to Examine Effect of OBE101 on Plasma Lipids in Patients Treated With Simvastatin


5/16/2007 12:20:56 PM

RAMAT GAN, Israel--(BUSINESS WIRE)--Obecure has launched a double-blinded, placebo-controlled Phase II clinical trial to evaluate the efficacy of the company’s OBE101 drug candidate in a third indication -- improving the plasma lipid profiles of patients treated with Simvastatin, the most widely prescribed, now generic, cholesterol-lowering drug.

Read at BioSpace.com


comments powered by Disqus
Obecure
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES